- Peptide (C)DYPAPGLQRPEDR, corresponding to amino acid residues 37-49 of rat ENT3 (Accession Q80WK7). Intracellular, N-terminus.
- Western blot analysis of rat liver lysate (lanes 1 and 4), mouse liver lysate (lanes 2 and 5) and rat kidney membranes (lanes 3 and 6):1-3. Anti-ENT3 (SLC29A3) Antibody (#ANT-053), (1:200).
4-6. Anti-ENT3 (SLC29A3) Antibody, preincubated with ENT3/SLC29A3 Blocking Peptide (#BLP-NT053).
Equilibrative nucleoside transporter 3 (ENT3) is responsible for transporting nucleotide synthesis precursors, such as hydrophilic nucleosides and nucleobases within cells1. ENT3 structure includes 11 transmembrane domains and a 51-residue hydrophilic N-terminal region containing two dileucine motifs that are characteristic of endosomal/lysosomal targeting sequences1,2.
ENT3 is encoded by the SLC29A3 gene and is expressed in several mouse and human tissues such as placenta, heart, neurons, and astrocytes. In addition, human ENT3 is predominantly expressed in mitochondria in human hepatocytes. Human ENTs are high-capacity transporters, bidirectional, Na+-independent with a wide substrate selectivity1,2.
The human ENT family consists of four members: ENT1- ENT4. Nucleoside transport function of ENT3 is maximal at pH 5.5 suggesting that the protein is localized to acidic intracellular compartments; probably lysosomes1,2.
Studies show that mutations in human ENT3 can cause various clinical disorders including H syndrome, pigmented hypertrichosis with insulin-dependent diabetes mellitus syndrome, lysosomal storage-like disorders and mitochondrial disorders1,2.
Species reactivity key:
Anti-ENT3 (SLC29A3) Antibody (#ANT-053) is a highly specific antibody directed against an epitope of the rat equilibrative nucleoside transporter 3. The antibody can be used in western blot analysis. It has been designed to recognize ENT3 from rat, mouse, and human samples.